Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Inclusion Criteria

• •A participant will be eligible for entry into the study if all of the following criteria are met per participant self-report:
• •Willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.
• •Lives in the United States.
• •Adult or late adolescent, ≥ 18 years of age at the time of informed consent.
• •Able to read and understand the English informed consent form.
• •The following will be investigator-reviewed: Participant has at least a 1-year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD), 3rd Edition:
• •i. Age of onset of migraines prior to 50 years of age
• •ii. Migraine attacks, on average, lasting 4-72 hours if untreated
• •iii. Per participant report, 4 or more migraine days per month within the last 3 months prior to the Screening Visit (a month is defined as 28 days)
• •iv. Four to fourteen migraine days during the run-in period
• •Is currently managing migraines with at least 1 prescription CGRP inhibitor therapy for the preventive or acute treatment of episodic or chronic migraine during the 3 months prior to screening.
• •Is the sole user of an iPhone with an iPhone operating system (iOS) 14 or later or a smartphone with an Android operating system (OS) 11 or later, and is willing to download and use the specified eDiary and Study App required by the protocol.
• •Is willing and able to receive SMS text messages and push messages on their smartphone.
• •Is the owner of, and has regular access to, an email address.
• •Has regular access to the Internet via cellular data plan and/or wifi.
• •Understands the use of and interest in the eDiary and the Study App during the screening period and the baseline visit (Day 1).